DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f1d6fa/antibodydrug_conj) has announced the addition of the "Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis" report to their offering.
This report provides the most complete compilation of information about antibody-drug conjugate (ADC) companies, technologies and products in R&D. A comprehensive analysis of the state of the art and key trends guides the reader through this complex subject. Stakeholders in the field of antibody-drug conjugates are analysed and their contribution to the growth ADC technology and products is assessed. A critical appraisal of the clinical results of active and discontinued ADC projects and products is provided. ADC technologies and products are challenged for their commercial value and growth potential.
The recent approval of Seattle Genetics' antibody-drug conjugate Adcetris has raised great enthusiasm among stakeholders in this field. Accelerated approval was based on stunning tumor response rates in relapsed Hodgkin's lymphoma and anaplastic large cell lymphoma. Analysts expect strong sales of the expensive therapy. However, the FDA request post-approval studies showing that the high response rates translate into improved survival and that the clinical benefit seen in a small study population of 160 patients can be confirmed in a larger population. Although these data do not have to delivered before 2018, Genentech will be the next company after Wyeth (now Pfizer) to come up with survival data of its solid tumor ADC trastuzumab emtansine expected for 2012-2014.
Reasons To Buy
- Understand available drug-linker technologies
- Identify key trends of novel ADC concepts and drug-linker technologies
- Understand the complexity of the chemistry, manufacturing and control of ADC products and which approaches can taken to reduce it
- Perceive a realistic target profile of current ADC compounds and how it can be improved
- Understand which tumor antigens are targeted by ADCs and their role
- See which companies can provide solutions
- Understand the commercial value of ADC technologies and ADC products
38 Companies Mentioned, including:
- Abbott
- Aeterna Zentaris
- Allozyne
- Alpha Cancer Technologies
- Anaphore
- Astellas Pharma (Agensys)
- AstraZeneca (MedImmune)
- Bayer Healthcare Pharmaceuticals
- Biogen Idec
- Biotest
- Celldex Therapeutics
- Centrose
- Genmab
- GlaxoSmithKline
- ImmunoGen
- Immunomedics
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Millennium: The Takeda Oncology Company
- Nerviano Medical Sciences
- Novartis
- Philogen
- Progenics Pharmaceuticals
- Roche (Genentech)
- Sanofi
- Seattle Genetics
- Spirogen
- Sutro Biopharma
- Tactic Pharma (Attenuon)
- Wilex (Heidelberg Pharma)
For more information visit http://www.researchandmarkets.com/research/f1d6fa/antibodydrug_conj